HCPCS Level II
Q5123
Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
Codes near Q5123
These sit next to Q5123 in the CMS Level II file. All Q codes
- Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
- Q5119Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
- Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
- Q5121Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
- Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
- Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
- Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
- Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 55513-0224-01 | Riabni | Amgen Inc | 10 |
| 55513-0326-01 | Riabni | Amgen Inc | 50 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.